FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091833792> ?p ?o ?g. }

• W3091833792 abstract "The COVID-19 outbreak and subsequent worldwide lockdowns have led to a temporal suspension of elective clinical care and many types of (non-COVID-19-related) medical research in many countries. Clinical trials are deeply affected on different levels by this ongoing crisis; trials are put on hold by sponsors and responsible authorities, patients cannot attend study visits, and research staff have restricted access to the hospital and research facilities or are transferred to provide COVID-19 care. A balance between protecting patients, healthcare workers, and researchers from COVID-19 on the one hand and the importance of continuing medical research that will eventually lead to new insights and treatments for other diseases on the other hand is searched for. During planning and initializing one of our new trials, we realized that prevention of spread of SARS-CoV-2 and rapid execution of clinical trials are not always contradictory. We would like to share our experience on designing and conducting a fully remotely conducted randomized clinical trial. We designed and are currently conducting a ‘’COVID-19 proof’’ single-center, prospective, randomized, double-blind, sham-controlled trial for a non-CE marked medical device. Institutional review board (IRB) approval, patient recruitment, informed consent procedure, dispensing the medical device, and trial monitoring visits are all done remotely while being in compliance with Good Clinical Practice (GCP) standards, the current ethical and legal framework, and the institutional and national COVID-19 lockdown measures. Our study population consists of 100 patients with moderately severe gastroesophageal reflux. It has been shown that body position during sleeping has an effect on nighttime gastroesophageal reflux.1 When sleeping in the left lateral decubitus position, the stomach is positioned below the esophagus, resulting in less reflux episodes compared to the right lateral position. The investigational medical device will gently vibrate when the body is in the right lateral position, training patients to sleep more on their left lateral position and thereby reducing nighttime gastroesophageal reflux. The intended study population for this trial typically uses self-care and over the counter products for their complaints and searches online for information. Therefore, we used the Google Ads platform to recruit study participants. If someone searches for one of the keywords in Google (“reflux during sleep,” “how to prevent acid during the night”), a targeted advertisement containing information about our study is displayed within the results. If they click on the advertisement, they are redirected to our hospital webpage with information of the study and contact information for participation. Additional information about the study is provided by regular mail, e-mail, and/or by (video) call by the investigator, and written informed consent is obtained. Next, all trial visits are conducted “virtual.” Daily questionnaires are automatically sent by e-mail to the participant, the medical device is delivered to the home address of the participants, and the investigator provides detailed study instructions by video call. Patients are regularly contacted by phone during the 5-week trial to ensure adherence to the trial protocol and respond to any questions. The whole process of designing the study, writing the study protocol, obtaining IRB approval, and first patient inclusion was less than 3 months. In the next two months, which fell during the first COVID-19 wave, we were able to recruit over 150 interested study participants who are currently in screening or are already randomized and participating in the study. It is estimated that the whole study duration (including data analysis and manuscript submission) will be within 12 months. Patient recruitment is essential for the successful completion of clinical trials and other forms of research involving human subjects. Twenty-five percent of the clinical trials are being stopped prematurely, with poor recruitment being the most frequently reported reason.2 Up to 61% of clinical trials fail to recruit their original recruitment target.3, 4 Digital platforms, such as Google, Facebook, Twitter, and Instagram, can be attractive tools for recruitment in medical research and show promising efficacy, while they are relatively unknown by clinical scientists.5, 6 Researchers can target potential study participants based on their personal information or search keywords and thereby reach and recruit a wider population faster and more cost-effective. Alternatively, a rare disease patient organization group on social media can be approached. The use of these platforms raises several ethical and privacy issues, that has been clustered in three sets of ethical challenges: (a) questions concerning the quality of research, (b) informed consent and privacy challenges, and (c) new power asymmetries based on access to data and control over technological infrastructures.7 For example, one simple click on a recruitment advert generates traceable data to the advertisement platform, Google AdWords in our study.8 While no unnecessary data are being collected by the investigator, the advertisement platform will learn that a specific individual has reflux complaints. This might be acceptable for the Google user, but when recruiting online for a clinical trial in a more stigmatizing disease, this could be otherwise. In addition, the reputation of social media platforms (such as Instagram, TikTok, and Facebook) regarding the respect for privacy has been widely discussed and thorough regulatory guidance and bioethical literature on the use of these social media platforms as recruitment tool for clinical trials is lacking.9, 10 We acknowledge that our clinical trial is well suited to be performed remotely, and this may not be possible in other clinical trials due to specific sample collection or investigations. However, we believe that in many clinical trials (a part of) the study procedures can be performed digitally or remotely which will ultimately benefit the patient and the investigator. Due to this crisis, we were forced to design and conduct our clinical trial fully remotely. Interestingly, this led to a more “patient-centered” and more efficient clinical trial. By sharing our experience, we aim to motivate other researchers to rethink the design of current and new clinical trials. AJB received research funding from Nutricia, Norgine, SST and Bayer and received speaker and/or consulting fees from Laborie, Arena, EsoCap, Medtronic, Dr. Falk Pharma, Calypso Biotech, Gossamer, Robarts, Reckett Benkiser, Regeneron, AstraZeneca and holds equity interests in SST." @default.
• W3091833792 created "2020-10-15" @default.
• W3091833792 creator A5025936343 @default.
• W3091833792 creator A5033250803 @default.
• W3091833792 creator A5044833174 @default.
• W3091833792 creator A5062957723 @default.
• W3091833792 creator A5069316397 @default.
• W3091833792 date "2020-10-06" @default.
• W3091833792 modified "2023-09-26" @default.
• W3091833792 title "Investigator initiated research in times of COVID‐19: Let’s go digital!" @default.
• W3091833792 cites W1495377470 @default.
• W3091833792 cites W1973836716 @default.
• W3091833792 cites W1975971094 @default.
• W3091833792 cites W2172268715 @default.
• W3091833792 cites W2531586652 @default.
• W3091833792 cites W2587949891 @default.
• W3091833792 cites W2603257905 @default.
• W3091833792 cites W2747587219 @default.
• W3091833792 cites W2947043267 @default.
• W3091833792 cites W2951838216 @default.
• W3091833792 doi "https://doi.org/10.1111/nmo.14011" @default.
• W3091833792 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7646011" @default.
• W3091833792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33025718" @default.
• W3091833792 hasPublicationYear "2020" @default.
• W3091833792 type Work @default.
• W3091833792 sameAs 3091833792 @default.
• W3091833792 citedByCount "2" @default.
• W3091833792 countsByYear W30918337922022 @default.
• W3091833792 countsByYear W30918337922023 @default.
• W3091833792 crossrefType "journal-article" @default.
• W3091833792 hasAuthorship W3091833792A5025936343 @default.
• W3091833792 hasAuthorship W3091833792A5033250803 @default.
• W3091833792 hasAuthorship W3091833792A5044833174 @default.
• W3091833792 hasAuthorship W3091833792A5062957723 @default.
• W3091833792 hasAuthorship W3091833792A5069316397 @default.
• W3091833792 hasBestOaLocation W30918337921 @default.
• W3091833792 hasConcept C118552586 @default.
• W3091833792 hasConcept C126322002 @default.
• W3091833792 hasConcept C141071460 @default.
• W3091833792 hasConcept C142724271 @default.
• W3091833792 hasConcept C153997805 @default.
• W3091833792 hasConcept C160735492 @default.
• W3091833792 hasConcept C168563851 @default.
• W3091833792 hasConcept C17744445 @default.
• W3091833792 hasConcept C199539241 @default.
• W3091833792 hasConcept C204787440 @default.
• W3091833792 hasConcept C2777106319 @default.
• W3091833792 hasConcept C2779134260 @default.
• W3091833792 hasConcept C2908647359 @default.
• W3091833792 hasConcept C3008058167 @default.
• W3091833792 hasConcept C502991105 @default.
• W3091833792 hasConcept C512399662 @default.
• W3091833792 hasConcept C524204448 @default.
• W3091833792 hasConcept C535046627 @default.
• W3091833792 hasConcept C545542383 @default.
• W3091833792 hasConcept C68122502 @default.
• W3091833792 hasConcept C71924100 @default.
• W3091833792 hasConcept C99454951 @default.
• W3091833792 hasConceptScore W3091833792C118552586 @default.
• W3091833792 hasConceptScore W3091833792C126322002 @default.
• W3091833792 hasConceptScore W3091833792C141071460 @default.
• W3091833792 hasConceptScore W3091833792C142724271 @default.
• W3091833792 hasConceptScore W3091833792C153997805 @default.
• W3091833792 hasConceptScore W3091833792C160735492 @default.
• W3091833792 hasConceptScore W3091833792C168563851 @default.
• W3091833792 hasConceptScore W3091833792C17744445 @default.
• W3091833792 hasConceptScore W3091833792C199539241 @default.
• W3091833792 hasConceptScore W3091833792C204787440 @default.
• W3091833792 hasConceptScore W3091833792C2777106319 @default.
• W3091833792 hasConceptScore W3091833792C2779134260 @default.
• W3091833792 hasConceptScore W3091833792C2908647359 @default.
• W3091833792 hasConceptScore W3091833792C3008058167 @default.
• W3091833792 hasConceptScore W3091833792C502991105 @default.
• W3091833792 hasConceptScore W3091833792C512399662 @default.
• W3091833792 hasConceptScore W3091833792C524204448 @default.
• W3091833792 hasConceptScore W3091833792C535046627 @default.
• W3091833792 hasConceptScore W3091833792C545542383 @default.
• W3091833792 hasConceptScore W3091833792C68122502 @default.
• W3091833792 hasConceptScore W3091833792C71924100 @default.
• W3091833792 hasConceptScore W3091833792C99454951 @default.
• W3091833792 hasIssue "11" @default.
• W3091833792 hasLocation W30918337921 @default.
• W3091833792 hasLocation W30918337922 @default.
• W3091833792 hasOpenAccess W3091833792 @default.
• W3091833792 hasPrimaryLocation W30918337921 @default.
• W3091833792 hasRelatedWork W118541628 @default.
• W3091833792 hasRelatedWork W1478203257 @default.
• W3091833792 hasRelatedWork W1532492608 @default.
• W3091833792 hasRelatedWork W2130977361 @default.
• W3091833792 hasRelatedWork W2137636999 @default.
• W3091833792 hasRelatedWork W2138818996 @default.
• W3091833792 hasRelatedWork W2406602197 @default.
• W3091833792 hasRelatedWork W2586435855 @default.
• W3091833792 hasRelatedWork W2599136485 @default.
• W3091833792 hasRelatedWork W2899356148 @default.
• W3091833792 hasVolume "32" @default.
• W3091833792 isParatext "false" @default.
• W3091833792 isRetracted "false" @default.
• W3091833792 magId "3091833792" @default.
• W3091833792 workType "article" @default.